• Etomoxir in Fatty Acid Oxidation Pathway Research Protocols

  2026-07-13

  Etomoxir empowers immunometabolic and metabolic disorder research by enabling precise inhibition of CPT-1 and DGAT, facilitating reproducible modulation of fatty acid oxidation pathways. This article unpacks optimized workflows, troubleshooting insights, and the transformative impact of standardized whole-blood metabolic assays.

• MOG (35-55) Peptide: Driving Precision in Autoimmune Encepha

  2026-07-13

  MOG (35-55) Peptide empowers researchers to model multiple sclerosis with unparalleled reproducibility, supporting mechanistic and therapeutic studies in neuroinflammation. Recent advances, including targeted PARP7 inhibition, unlock novel assay readouts and disease-modifying strategies in EAE workflows.

• Wnt and BMP Patterning of Hemichordate Neuroectoderm: Insigh

  2026-07-12

  This study delineates how Wnt and BMP signaling pathways establish the anterior neuroectoderm (ANE) in the indirect-developing hemichordate Ptychodera flava. By mapping gene expression and pathway function during gastrulation, the research clarifies evolutionary conservation and divergence in deuterostome axis patterning, offering a comparative framework for developmental and translational biology.

• HyperFluor™ 488 Antibody: Illuminating FXR LLPS and Advanced

  2026-07-10

  Explore how the HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody, an Alexa Fluor 488 conjugated secondary antibody from APExBIO, enables unprecedented clarity in visualizing FXR-driven liquid–liquid phase separation. This article uniquely bridges mechanistic cell biology with practical assay optimization for cutting-edge virology and cell imaging workflows.

• In Vitro Drug Response Evaluation: Advances and Implications

  2026-07-09

  Schwartz's dissertation introduces a nuanced framework for evaluating anti-cancer drug responses in vitro, distinguishing between proliferative arrest and cell death through dual-metric approaches. These innovations clarify drug mechanism assessment and have practical implications for the design and interpretation of DNA replication and topoisomerase II inhibition assays.

• BHPF Inhibits GPER1: New Mechanism in Neuroblastoma Apoptosi

  2026-07-09

  This study reveals that fluorene-9-bisphenol (BHPF), a BPA substitute, acts as a novel inhibitor of the G protein-coupled estrogen receptor 1 (GPER1) in human neuroblastoma cells. By integrating molecular dynamics, site-directed mutagenesis, and cell-based assays, the research uncovers BHPF's unique binding mode and antagonistic action, informing future health risk assessments of environmental bisphenols and providing a framework for dissecting GPER-mediated pathways.

• RG108: Transforming Epigenetic Modulation in Translational O

  2026-07-08

  This thought-leadership article explores how RG108, a potent DNA methyltransferase inhibitor, is redefining epigenetic research and experimental strategy in translational oncology. By integrating mechanistic insights, benchmarking, and actionable guidance, we reveal how RG108 empowers researchers to reactivate silenced tumor suppressor genes, optimize assay outcomes, and bridge preclinical discovery with future clinical impact. We draw on recent literature and comprehensive reviews to underscore the importance of precise epigenetic modulation and position RG108 as a cornerstone for next-generation cancer research.

• Acetoacetic Acid Sodium Salt in Energy Metabolism Research

  2026-07-08

  Acetoacetic acid sodium salt empowers high-sensitivity metabolic assays, offering reproducibility and translational value for diabetes and fatty acid catabolism studies. This guide delivers actionable protocols, troubleshooting tips, and workflow enhancements—bridging bench research and clinical insight.

• Selective Nanomolar IRAP Inhibitors from α-Hydroxy-β-Amino A

  2026-07-07

  The referenced study introduces a stereoselective synthetic route to α-hydroxy-β-amino acid derivatives of bestatin, yielding highly selective, nanomolar inhibitors of insulin-regulated aminopeptidase (IRAP). This work advances chemical probe design for M1 aminopeptidases, providing both methodological innovation and mechanistic insight for applications in immunology and drug discovery.

• EdU Imaging Kits (Cy5): Precision Cell Proliferation Analysi

  2026-07-07

  EdU Imaging Kits (Cy5) empower researchers to quantify S-phase DNA synthesis with unmatched specificity and workflow simplicity, outperforming traditional BrdU assays. Their click chemistry platform preserves cell structure, enabling reliable results for fluorescence microscopy and flow cytometry applications, even in challenging genotoxicity or vascular remodeling studies.

• ICAA Modulates RIP3 to Counteract Ang II-Induced Cardiac Hyp

  2026-07-06

  This study uncovers how isochlorogenic acid A (ICAA) inhibits angiotensin II-induced cardiac hypertrophy by directly suppressing RIP3 phosphorylation and downstream CaMKII activation. The findings identify the RIP3/CaMKII axis as a novel therapeutic target, with implications for advancing mechanistic precision in cardiovascular disease research.

• WP1066, JAK2/STAT3 Inhibitor: Applied Workflows & Innovation

  2026-07-06

  WP1066, a potent and cell-permeable JAK2/STAT3 inhibitor, enables precise modulation of cancer and immune pathways in both in vitro and in vivo models. This article delivers actionable protocols, troubleshooting guidance, and cross-domain insights, drawing on the latest research in oncology and regenerative medicine.

• 7ACC2: Monocarboxylate Transporter 1 Inhibitor in Cancer Res

  2026-07-05

  7ACC2, a potent dual-action inhibitor of MCT1 and mitochondrial pyruvate transport, empowers researchers to dissect and therapeutically exploit cancer metabolic dependencies. This guide details stepwise experimental workflows, troubleshooting strategies, and the latest insights from immunometabolic research, positioning 7ACC2 as an indispensable tool for advanced tumor microenvironment studies.

• URB597 (KDS-4103): Optimizing FAAH Inhibition in Pain Models

  2026-07-04

  URB597 (KDS-4103) elevates endocannabinoid tone with exceptional selectivity, enabling rigorous dissection of neuroinflammation and neuroplasticity mechanisms in vivo. This guide translates recent multi-dimensional pain research into robust workflows, troubleshooting, and practical protocol enhancements for FAAH inhibition using APExBIO's URB597.

• Modeling Stroma-Driven Chemoresistance in Pancreatic Cancer

  2026-07-03

  Schuth et al. introduce a 3D co-culture platform combining patient-derived pancreatic cancer organoids with matched cancer-associated fibroblasts to unravel the stromal influences on chemoresistance. Their findings highlight the critical role of stromal interactions—especially CAF-induced EMT signaling—in modulating drug responses, offering a more physiologically relevant system for drug screening and mechanistic studies.

15063 records 1/1005 page Next 12345 下5页 Last page